Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy

Abstract

BackgroundDegenerative disc disease (DDD) is a common cause of lower back pain with radicular symptoms and has a significant socioeconomic impact given the associated disability. Limited effective conservative therapeutic options result in many turning to surgical alternatives for management, which vary in the rate of success and also carry an increased risk of morbidity and mortality associated with the procedures. Several animal based studies and a few human pilot studies have demonstrated safety and suggest efficacy in the treatment of DDD with mesenchymal stem cells (MSCs). The use of bone marrow-derived MSCs for the treatment of DDD is promising and in the present study we report on the safety and efficacy findings from a registry based proof of concept study using a percutaneous intradiscal injection of cultured MSCs for the management of DDD with associated radicular symptoms.MethodsThirty-three patients with lower back pain and disc degeneration with a posterior disc bulge diagnosed on magnetic resonance imaging (MRI) met the inclusion criteria and were treated with culture-expanded, autologous, bone marrow-derived MSCs. Prospective registry data was obtained at multiple time intervals up to 6 years post-treatment. Collected outcomes included numeric pain score (NPS), a modified single assessment numeric evaluation (SANE) rating, functional rating index (FRI), measurement of the intervertebral disc posterior dimension, and adverse events.ResultsThree patients reported pain related to procedure that resolved. There were no serious adverse events (i.e. death, infection, or tumor) associated with the procedure. NPS change scores relative to baseline were significant at 3, 36, 48, 60, and 72 months post-treatment. The average modified SANE ratings showed a mean improvement of 60% at 3 years post-treatment. FRI post-treatment change score averages exceeded the minimal clinically important difference at all time points except 12 months. Twenty of the patients treated underwent post-treatment MRI and 85% had a reduction in disc bulge size, with an average reduction size of 23% post-treatment.ConclusionsPatients treated with autologous cultured MSCs for lower back pain with radicular symptoms in the setting of DDD reported minor adverse events and significant improvements in pain, function, and overall subjective improvement through 6 years of follow-up.NCT03011398. A Clinical Registry of Orthobiologics Procedures. https://clinicaltrials.gov/ct2/show/NCT03011398?term=orthobiologics&rank=1

Use of Allogeneic Hypoxic Mesenchymal Stem Cells For Treating Disc Degeneration in Rabbits

“…In one pilot study using autologous bone marrow stem cell JOURNAL OF ORTHOPAEDIC RESEARCH ® JUNE 2019 injection, investigators observed a significant improvement of pain and disability in 3 months. 37 Similarly, Centeno et al 38 demonstrated that significant improvement of impairment and pain relieve in 33 patients receiving autologous BM-MSC injection though 6 years of follow up. Additionally, 85% of the patients had a reduction in disc bulge size.…”

Photopolymerizable biogel scaffold seeded with mesenchymal stem cells: safety and efficacy evaluation of novel treatment for intervertebral disc degeneration

“…One recent study by Centeno et al examined percutaneous injection of MSCs into in vivo human lumbar discs with hernation of the NP; they described a low complication rate, clinical improvement and decrease in the size of disc herniation on long term follow up. 20 When looking at intradiscal injection of MSCs and hyaluronic acid reported no adverse events and improved clinical outcome measures. 21 Of the improved patients, 50% had increased water content within the disc at longterm follow up, though no changes were noted in radiographic measures of disc degeneration.…”

“…There is substantial potential for intradiscal injectable therapeutics for treating IDD. One recent study by Centeno et al examined percutaneous injection of MSCs into in vivo human lumbar discs with hernation of the NP; they described a low complication rate, clinical improvement and decrease in the size of disc herniation on long term follow up . When looking at intradiscal injection of MSCs and hyaluronic acid scaffold in a clinical trial of 10 patients, Kumar et al reported no adverse events and improved clinical outcome measures .…”

Regenerative Medicine for Axial and Radicular Spine‐Related Pain: A Narrative Review

“…Four studies analyzed the effects of intradiscal injection of MSCs. Three showed improvement in measured pain and disability scores with follow‐up periods of at least 1 year . The lone negative study showed no improvement in numeric pain scores at 1 year after intradiscal injection of BMAC‐MSCs followed by a 2‐week course of hyperbaric oxygen therapy …”